-
Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations
•
Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation (Sinopharm), has been dismissed from his role as a delegate to the 14th National People’s Congress due to suspicions of serious disciplinary and legal violations, as determined by the Standing Committee of the National People’s…
-
Neusoft Medical Systems Partners with West China Hospital to Boost Indigenous Medical Tech Innovation
•
China-based Neusoft Medical Systems Co., Ltd has entered into a strategic partnership with West China Hospital to establish the “West China Hospital – Neusoft Medical High-end Medical Equipment and Hospital High-Quality Development Innovation Center.” The collaboration aims to enhance the innovative application of domestic high-end medical equipment and medical imaging…
-
AbelZeta Pharma’s CAR-T Therapy C-CAR031 Receives Implicit Approval for Clinical Study in China
•
Sino-US biotechnology company AbelZeta Pharma Inc., operating in Rockville, Maryland, and Shanghai, China, has received implicit approval for its autologous armored GPC3-targeted chimeric antigen receptor (CAR) T cell therapy, C-CAR031, developed by its subsidiary, Shanghai Cellular Biopharmaceutical Group Ltd. The therapy is intended for the treatment of GPC3+ advanced or…
-
Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups
•
Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade association, according to Fierce Pharma. This move makes Takeda the fourth major company to leave BIO since December of the previous year, following the exits of Pfizer and…
-
AstraZeneca Reports 19% YOY Revenue Growth in Q1 2024, Driven by Oncology and R&I
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released an impressive set of financial results for the first quarter of 2024, with overall revenues increasing by 19% year-on-year (YOY) in constant currency terms to USD 12.68 billion. Product sales soared 18% YOY, reaching USD 12.18 billion. The company’s business units…
-
MicroPort CardioFlow Medtech’s VitaFlow Liberty Receives CE Mark for European Expansion
•
China-based MicroPort Scientific Corp (HKG: 0853), a leading medical device company, announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has secured the CE mark for its VitaFlow Liberty transcatheter aortic valve and its recyclable delivery system. This regulatory approval paves the way for the product’s market entry…
-
Allgens Medical Technology to Acquire German Dental Implant Maker HumanTech Dental for EUR 3.25 Million
•
Beijing-based Allgens Medical Technology Co., Ltd (SHA: 688613), specializing in regenerative medicine materials and implantable devices, has announced plans to acquire all outstanding shares of HumanTech Dental GmbH, a German dental implant manufacturer, for a consideration of EUR 3.25 million (USD 3.5 million). Established in 2017, HumanTech Dental has been…
-
Wuhan Bio-Raid Biotechnology Secures NMPA Approval for First-in-Class CD99-Targeted CAR-T Therapy
•
Wuhan Bio-Raid Biotechnology Co., Ltd, a leading developer of chimeric antigen receptor (CAR)-T cell therapies in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its proprietary BRD-03. This autologous CD99-targeted CAR-T therapy is classified as a Category 1 biologic therapeutic…
